Story perspectives

Japan Approves Controversial Stem Cell Therapies for Parkinson's and Heart Failure

2/25/2026

Summary

Story summary

Japan will grant conditional approval for two stem cell therapies, Amchepry and ReHeart, to treat Parkinson's disease and severe heart failure.
The therapies use induced pluripotent stem cells and have small trials with seven and eight patients, yielding limited data.
Experts Paul Knoepfler and Hiroshi Kawaguchi warn about small trial sizes and risks such as tumor formation, while critics say weak regulatory standards could erode public trust and slow progress.

1 of 1

Story summary

Japan will grant conditional approval for two stem cell therapies, Amchepry and ReHeart, to treat Parkinson's disease and severe heart failure.
The therapies use induced pluripotent stem cells and have small trials with seven and eight patients, yielding limited data.
Experts Paul Knoepfler and Hiroshi Kawaguchi warn about small trial sizes and risks such as tumor formation, while critics say weak regulatory standards could erode public trust and slow progress.